drug_type
RELEVANT_DRUG
intervention_type
Biological (cellular therapy)
drug_description
Autologous CD8+ and CD4+ T cells genetically engineered to express a high-affinity T-cell receptor specific for the KRAS G12V peptide presented by HLA-A*11:01, designed to recognize and kill KRAS G12V–positive tumor cells (adoptive cellular therapy).
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
T-Lymphocytes
drug_category
ENGINEERED TCR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous CD8+ and CD4+ T cells engineered to express a high-affinity TCR specific for the KRAS G12V peptide presented by HLA-A*11:01. Upon HLA-restricted recognition of KRAS G12V on tumor cells, the transgenic TCR triggers T-cell activation, cytokine release, and perforin/granzyme-mediated cytotoxicity, selectively eliminating KRAS G12V–positive tumor cells.
drug_name
FH-A11KRASG12V-TCR (AFNT-111) TCR-engineered autologous T cells
nct_id_drug_ref
NCT06043713